Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 3
1981 8
1982 23
1983 33
1984 17
1985 23
1986 21
1987 18
1988 24
1989 19
1990 12
1991 25
1992 22
1993 27
1994 34
1995 45
1996 33
1997 37
1998 41
1999 24
2000 25
2001 25
2002 37
2003 28
2004 26
2005 23
2006 20
2007 24
2008 37
2009 41
2010 35
2011 33
2012 39
2013 25
2014 16
2015 30
2016 24
2017 23
2018 20
2019 20
2020 17
2021 22
2022 14
Text availability
Article attribute
Article type
Publication date

Search Results

1,042 results
Results by year
Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Kanuka honey versus aciclovir for the topical treatment of herpes simplex labialis: a randomised controlled trial.
Semprini A, Singer J, Braithwaite I, Shortt N, Thayabaran D, McConnell M, Weatherall M, Beasley R. Semprini A, et al. BMJ Open. 2019 May 14;9(5):e026201. doi: 10.1136/bmjopen-2018-026201. BMJ Open. 2019. PMID: 31092654 Free PMC article. Clinical Trial.
OBJECTIVE: To compare New Zealand medical grade kanuka honey with topical aciclovir for the treatment of herpes simplex labialis. DESIGN: Prospective parallel randomised controlled open-label superiority trial. ...CONCLUSION: There was no evidence of a difference in effica …
OBJECTIVE: To compare New Zealand medical grade kanuka honey with topical aciclovir for the treatment of herpes simplex labialis. DES …
Early treatment with prednisolone or acyclovir in Bell's palsy.
Sullivan FM, Swan IR, Donnan PT, Morrison JM, Smith BH, McKinstry B, Davenport RJ, Vale LD, Clarkson JE, Hammersley V, Hayavi S, McAteer A, Stewart K, Daly F. Sullivan FM, et al. N Engl J Med. 2007 Oct 18;357(16):1598-607. doi: 10.1056/NEJMoa072006. N Engl J Med. 2007. PMID: 17942873 Free article. Clinical Trial.
After 9 months, these proportions were 94.4% for prednisolone and 81.6% for no prednisolone (P<0.001) and 85.4% for acyclovir and 90.8% for no acyclovir (adjusted P=0.10). For patients treated with both drugs, the proportions were 79.7% at 3 months (P<0.001) a …
After 9 months, these proportions were 94.4% for prednisolone and 81.6% for no prednisolone (P<0.001) and 85.4% for acyclovir and …
Once-daily valacyclovir to reduce the risk of transmission of genital herpes.
Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, Douglas JM Jr, Paavonen J, Morrow RA, Beutner KR, Stratchounsky LS, Mertz G, Keene ON, Watson HA, Tait D, Vargas-Cortes M; Valacyclovir HSV Transmission Study Group. Corey L, et al. N Engl J Med. 2004 Jan 1;350(1):11-20. doi: 10.1056/NEJMoa035144. N Engl J Med. 2004. PMID: 14702423 Free article. Clinical Trial.
Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults.
Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Beutner KR, et al. Antimicrob Agents Chemother. 1995 Jul;39(7):1546-53. doi: 10.1128/AAC.39.7.1546. Antimicrob Agents Chemother. 1995. PMID: 7492102 Free PMC article. Clinical Trial.
Acyclovir treatment of acute herpes zoster speeds rash healing and decreases pain and ocular complications. The limited oral bioavailability of acyclovir necessitates frequent dosing. Valaciclovir, the l-valyl ester of acyclovir, is rapidly and almost complet
Acyclovir treatment of acute herpes zoster speeds rash healing and decreases pain and ocular complications. The limited oral bioavail
PEPtalk2: results of a pilot randomised controlled trial to compare VZIG and aciclovir as postexposure prophylaxis (PEP) against chickenpox in children with cancer.
Bate J, Baker S, Breuer J, Chisholm JC, Gray J, Hambleton S, Houlton A, Jit M, Lowis S, Makin G, O'Sullivan C, Patel SR, Phillips R, Ransinghe N, Ramsay ME, Skinner R, Wheatley K, Heath PT. Bate J, et al. Arch Dis Child. 2019 Jan;104(1):25-29. doi: 10.1136/archdischild-2017-314212. Epub 2018 May 5. Arch Dis Child. 2019. PMID: 29730641 Clinical Trial.
OBJECTIVE: To determine the likely rate of patient randomisation and to facilitate sample size calculation for a full-scale phase III trial of varicella zoster immunoglobulin (VZIG) and aciclovir as postexposure prophylaxis against chickenpox in children with cancer. ...IN …
OBJECTIVE: To determine the likely rate of patient randomisation and to facilitate sample size calculation for a full-scale phase III trial …
Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis.
Barron BA, Gee L, Hauck WW, Kurinij N, Dawson CR, Jones DB, Wilhelmus KR, Kaufman HE, Sugar J, Hyndiuk RA, et al. Barron BA, et al. Ophthalmology. 1994 Dec;101(12):1871-82. doi: 10.1016/s0161-6420(13)31155-5. Ophthalmology. 1994. PMID: 7997323 Clinical Trial.
By 16 weeks, 38 patients (75%) in the acyclovir group and 39 patients (74%) in the placebo group had failed treatment. ...Visual acuity improved over 6 months in more patients in the acyclovir group than in the placebo group....
By 16 weeks, 38 patients (75%) in the acyclovir group and 39 patients (74%) in the placebo group had failed treatment. ...Visual acui …
Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients.
Höglund M, Ljungman P, Weller S. Höglund M, et al. J Antimicrob Chemother. 2001 Jun;47(6):855-61. doi: 10.1093/jac/47.6.855. J Antimicrob Chemother. 2001. PMID: 11389118 Clinical Trial.
The objective of this study was to evaluate the comparability of systemic aciclovir exposure at steady state in immunocompromised patients following oral valaciclovir 1000 mg tds and intravenous (iv) aciclovir 5 mg/kg tds. ...The mean absolute bioavailability of …
The objective of this study was to evaluate the comparability of systemic aciclovir exposure at steady state in immunocompromised pat …
Lip creams with propolis special extract GH 2002 0.5% versus aciclovir 5.0% for herpes labialis (vesicular stage) : Randomized, controlled double-blind study.
Jautová J, Zelenková H, Drotarová K, Nejdková A, Grünwaldová B, Hladiková M. Jautová J, et al. Wien Med Wochenschr. 2019 May;169(7-8):193-201. doi: 10.1007/s10354-018-0667-6. Epub 2018 Nov 7. Wien Med Wochenschr. 2019. PMID: 30406509 Free PMC article. Clinical Trial.
A lip cream with special propolis extract GH 2002 at a concentration of 0.5% (199 patients) was tested against aciclovir 5% (198 patients) in the treatment of episodes of herpes labialis under double-blind conditions. ...The predefined clinical situation was reached after …
A lip cream with special propolis extract GH 2002 at a concentration of 0.5% (199 patients) was tested against aciclovir 5% (198 pati …
Lack of bioequivalence between two aciclovir tablets in healthy subjects.
Amini H, Javan M, Gazerani P, Ghaffari A, Ahmadiani A. Amini H, et al. Clin Drug Investig. 2008;28(1):47-53. doi: 10.2165/00044011-200828010-00006. Clin Drug Investig. 2008. PMID: 18081360 Clinical Trial.
OBJECTIVE: This study aimed to compare the systemic bioavailability of two aciclovir tablets, Rouz-Aciclovir (test) and Zovirax (reference), in 12 healthy volunteers. METHODS: In a crossover design, each subject received a single oral dose of aciclovir 400 mg …
OBJECTIVE: This study aimed to compare the systemic bioavailability of two aciclovir tablets, Rouz-Aciclovir (test) and Zovira …
1,042 results